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Introduction
Breast cancer is the most common cancer among women, as it is diagnosed in 1x106 women 
in the world each year. The incidence of breast tumor development in women differs with 
age, mammary gland mass and exposure to endogenous and exogenous hormones . However, 
the function, molecular regulation, and interaction of genetic alterations in carcinogenesis, as 
well as those of tumor cell migration and invasion, and metastasis of breast carcinomas are 
not fully understood. As metastasis is a major challenge in cancer treatment, determination of 
molecular markers of metastatic potential and therefore understanding the process of metas-
tatic tumor progression are important. Recently, comprehensive transcriptome profiling of 
normal breast, noninvasive breast tumor and invasive breast cancer cell lines identified lysyl 
oxidase (LOX) as a possible marker gene based on its differential expression . In addition, 
upregulated LOX expression and activity have been reported in breast cancer tissues and in-
vasive/metastatic breast cancer cell lines as well. Lysyl oxidase has been primarily recognized 
as a matrix-crosslinking enzyme; hence regulators and interacting factors contributing to its 
novel role in breast cancer development and progression are yet to be discovered. Results of 
our previous yeast two-hybrid screens demonstrated the interaction of LOX with the preg-
nancy-specific hormone, placental lactogen (PL). PL is a member of the somatotro-
pin/prolactin hormone family, expressed solely in the placental syncytiotrophoblasts under 
physiological conditions, that has a role in lactogenesis and the growth and development of 
the fetus. Similarly to growth hormone and prolactin, expression of PL has been associated 
with tumors of mammary origin. However, its role in tumorigenesis as well as the role of the 
LOX-PL interaction in such processes, remains to be elucidated.
Objectives
The goal of this work was to verify the novel LOX-PL interaction that likely promotes LOX’s 
function during tumorigenesis, and to characterize this interaction and evaluate its biological 
significance. The following aims were proposed:
Specific Aim 1.
Determine the specificity of the interaction between LOX and PL represented by multiple 
clones in yeast two-hybrid screen using yeast direct studies.
Test the specificity of the interaction of the library proteins with the LOX bait proteins 
in yeast following the identification of LOX-interacting partners in yeast two-hybrid 
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screening by directly co-transforming various combinations of bait and target plasmids 
into yeast and assaying for reporter gene activation.
Specific Aim 2.
Confirm and characterize the LOX-PL interaction in vitro.
a) Generate expression constructs for LOX and LOX fragments.
b) Express and purify recombinant LOX proteins in quantities sufficient for further in 
vitro biochemical experiments.
c) Perform in vitro binding analysis using pull-down and Far-Western assays.
d) Perform solid phase binding assays to measure the equilibrium disassociation con-
stant (Kd) of the protein interaction, and determine LOX-binding affinity for hGH and 
hPRL, two related members of the hormone family.
Specific Aim 3.
Investigate LOX-PL interactions  in vivo.
a) Test LOX and PL expression in breast cancer tissues by immunofluorescent staining 
and confirm their co-expression in mammary neoplasms that is also supported by data 
from the literature.
b) Identify an appropriate in vivo model to test the native LOX-PL complex using co-
immunoprecipitation.
Specific Aim 4.
Explore the effects of the identified LOX-PL protein interactions on the catalytic activity of 
LOX.
Perform enzyme activity assays in order to clarify the nature of the protein interactions
and determine whether it is an enzyme-substrate or enzyme-inhibitor/enhancer rela-
tion.
Specific Aim 5.
 Investigate the biological significance of the identified protein interactions.
a) Generate stable cell lines overexpressing either LOX or PL or both of the proteins 
for further phenotypic analysis.
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b) Study the cellular phenotype including proliferative and migratory characteristics of 
the overexpressing cell lines in order to determine the biological role of the protein 
interaction.
Materials and Methods
Over the course of this PhD study, I was validating and characterizing the protein interaction 
of lysyl oxidase and placental lactogen, identified in previous yeast two-hybrid screens. For 
the biochemical analysis, recombinant GST-LOX deletion constructs were cloned, expressed 
and purified from E. coli bacteria. Yeast direct interaction-studies, solid phase binding assays, 
pull-down assays verified the LOX-PL interaction in vitro, and the binding affinity was 
determined. In vitro enzyme activity assays were used to test the effect of PL-binding on the 
enzymatic activity of LOX. Expression of the proteins in breast tumor tissue sections was 
evaluated by co-immunostaining and confocal microscopy. Western blot analysis was used to 
evaluate expression of the proteins in breast cancer cell lines, and the interaction was tested in 
vivo by co-immunoprecipitation trials. The individual and combined effects of LOX and PL 
overexpression on cell behavior was assessed in immortalized normal mammary epithelial 
cells transduced by a lentiviral system to stably express LOX and/or PL. Changes in cell 
proliferation was studied in cell proliferation assays. Alterations of cell motility was assessed 
in these transduced cell lines first by staining the actin cytoskeleton to reveal its possible 
rearrangement, then by performing cell migration assays.
Results
In yeast direct interaction trials, pull-down and Far-Western assays we found that LOX 
indeed binds PL. Moreover, we discovered that in addition to LOX, another member of the 
enzyme family, LOXL2 also binds PL. 
Recombinant, GST-tagged LOX deletion constructs were successfully cloned and 
expressed in E. coli. Following initial, partly successful attempts to purify these GST-LOX 
proteins in soluble form, we were able to purify them from the inclusion body fraction in 
quantities sufficient for further in vitro biochemical analysis.
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In solid phase binding assays we were able to narrow down the LOX region (amino acids 
169-348) that participates in PL-binding most likely in concert with LOX’s CRL domain. 
We demonstrated that LOX does not only bind PL, but has an affinity to two homologous 
members of the hormone family, growth hormone and prolactin as well, although LOX’s 
binding affinity is approximately two orders of magnitude lower to these hormones that to its 
natural substrates.
In enzyme activity assays we determined that PL is not a substrate of LOX, as the enzyme 
did not show any activity toward the hormone. 
Since LOX retains its enzymatic activity towards cadaverine as substrate in the presence 
of PL, we revealed that PL has neither an inhibitory, nor a stimulatory effect on LOX activity.
Co-expression LOX and PL was tested by co-immunostaining on a breast cancer tissue 
macroarray, as both LOX and PL expression in breast tumors have been previously reported. 
Upon demonstrating the co-expression of the proteins in tumor samples of mammary origin, 
we investigated their expression in breast cancer cell lines by Western blotting, and showed 
that the highly invasive and metastatic breast cancer cell lines Hs578T and MDA-MB231 did 
not only express LOX at elevated levels, but PL as well.
In co-immunoprecipitation studies using the PL and LOX co-expressing Hs578T breast 
cancer cells, we confirmed that the LOX-PL interaction can also occur in vivo.
In order to investigate the individual and combined effects of LOX and PL overexpression 
in mammary epithelium, we transduced immortalized normal mammary epithelial MCF-10A 
cells to stably express either or both of the proteins. As PL but not LOX has been 
demonstrated to induce cell proliferation, we tested cell proliferation of the stably transduced 
cell lines. We have found that overexpression of PL resulted in significantly elevated 
proliferation rates, and its co-expression with LOX further increased cell proliferation. 
Overexpression of LOX alone did not result in such effect.
Another cellular process we studied was cell migration, as overexpression of LOX 
reportedly leads to a more migratory phenotype in poorly invasive, nonmetastatic breast 
cancer cell lines. First, we stained the actin cytoskeleton using phalloidin to evaluate the 
possible actin rearrangement that would suggest changes towards a more motile phenotype. 
Interestingly, we observed the rearrangement of the actin cytoskeleton and the formation of 
numerous, long filopodia in all stably transduced cell lines. Therefore we decided to test the 
migratory abilities of these cell lines in cell migration assays. Our results reveal, that 
overexpression of LOX alone is not sufficient to induce a more migratory phenotype in 
normal breast epithelial cells, unlike in poorly invasive breast cancer cells. Similarly, 
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overexpression of PL alone does not induce changes in migratory behavior. The cell lines co-
expressing both LOX and PL, however showed a significant increase in their cell motility.
Conclusions
In this study the interaction of the extracellular matrix enzyme, lysyl oxidase with the 
hormone placental lactogen was confirmed and characterized in in vitro assays. In addition to 
LOX, we demonstrated that another member of the enzyme family, LOXL2 is able to bind PL 
as well. Interestingly, these enzymes binding PL, LOX and LOXL2 have both been impli-
cated in tumorigenic processes. Our results did not only support LOX binding to PL but also
suggested binding to GH and PRL, two other members of the somatotropin/prolactin hormone 
family that are reportedly potent oncogenes as well.
In addition, in vitro amine oxidase activity assays showed that PL is neither a substrate 
nor an inhibitor of LOX. Therefore the exact mechanism and fashion of their interaction re-
mains to be elucidated. 
Using fluorescence-labeled immunostaining on a tissue macroarray, we detected LOX and 
PL expression in and around breast tumor cells. Subsequently, we tested protein expression of 
breast cancer cell lines, and found elevated PL expression in highly invasive cell lines, where 
LOX expression was also increased. Furthermore, we showed PL expression in poorly inva-
sive cells at elevated and low levels, respectively. Since the highly invasive and metastatic 
breast cancer cell lines express both PL and LOX, we decided to study their individual and 
combined effects on cell behavior by overexpressing and co-expressing these proteins in im-
mortalized normal breast epithelial cells. LOX plays a role in promoting cell migration, while 
PL was shown to induce cell proliferation, thus we tested these processes. Stably transduced 
MCF-10A normal mammary epithelial cells co-expressing PL and LOX had significantly in-
creased proliferation rates compared to the parental and the PL-expressing cells, while LOX 
alone had no effect on proliferation. Therefore, the co-expression of LOX with PL appears to 
enhance the proliferation-inducing effect of PL. Co-expressing cells in addition showed a sig-
nificantly higher migratory rate compared to cells expressing either or none of these proteins. 
Our results demonstrated that LOX, in addition to promoting tumor cell invasion through a 
H2O2-induced FAK/Src activation that we have described earlier, may further induce tumor 
cell migration in interaction with PL by activating independent signaling.
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